What does the future hold for prostate cancer treatment?
Researchers at the Dana-Farber Cancer Institute (DFCI) continuously pursue research targeted toward improving the treatment of prostate cancer. Included among this body of work is the six-month trial Docetaxel plus 6-month Androgen Suppression and Radiation Therapy vs 6-Month Androgen Suppression and Radiation Therapy for Patients with High-Risk Localized or Locally Advanced Prostate Cancer, which is investigating the effectiveness of the chemotherapy drug docetaxel (Taxotere) in treating men with high risk cancer. Visit DFCI’s clinical trials website to learn more about the Taxotere study and other clinical trials.